![\"\"](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/07\/1785163691_844_logo.jpg\"){kind=logo}
\u00a0<\/p>\n\u00a0<\/p>\n
UNITED STATES<\/p>\n
SECURITIES AND EXCHANGE COMMISSION<\/p>\n
Washington, D.C. 20549<\/p>\n
\u00a0<\/p>\n
________________<\/p>\n
\u00a0<\/p>\n
FORM 6-K<\/p>\n
________________<\/p>\n
\u00a0<\/p>\n
REPORT OF FOREIGN PRIVATE ISSUER<\/p>\n
\u00a0<\/p>\n
Pursuant to Rule 13a-16 or 15d-16<\/p>\n
of the Securities Exchange Act of 1934<\/p>\n
\u00a0<\/p>\n
July 27, 2026<\/p>\n
________________<\/p>\n
\u00a0<\/p>\n
NOVO NORDISK A\/S<\/p>\n
\u00a0(Exact name
\nof Registrant as specified in its charter)<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Novo All\u00e9 1<\/p>\n
DK- 2880, Bagsvaerd<\/p>\n
Denmark<\/p>\n
(Address of principal executive offices)<\/p>\n
________________<\/p>\n
\u00a0<\/p>\n
Indicate by check mark whether the registrant files or will file annual reports under
\ncover of Form 20-F or Form 40-F<\/p>\n
\u00a0<\/p>\n
Form 20-F \u2612\u00a0\u00a0\u00a0\u00a0\u00a0
\n \u00a0\u00a0\u00a0\u00a0\u00a0Form 40-F \u2610<\/p>\n
\u00a0\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/07\/1785163692_591_ca.jpg\")
\u00a0<\/p>\n
\u00a0<\/p>\n
Novo Nordisk A\/S \u2013 Share repurchase programme<\/p>\n
\u00a0<\/p>\n
Bagsv\u00e6rd, Denmark, 27 July 2026 \u2013 On 6 May 2026, Novo Nordisk
\ninitiated a share repurchase programme in accordance with Article 5 of Regulation No 596\/2014 of the European Parliament and Council
\nof 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016\/1052 of 8 March 2016 (the “Safe Harbour Rules”). This
\nprogramme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning
\n4 February 2026.<\/p>\n
\u00a0<\/p>\n
Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares
\nfor an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.<\/p>\n
\u00a0<\/p>\n
Since the announcement 20 July 2026, the following transactions have been made:<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Number
\n of<\/p>\n
B
\n shares<\/p>\n
Average<\/p>\n
purchase
\n price<\/p>\n
Transaction<\/p>\n
value,
\n DKK<\/p>\n
Accumulated, last announcement
\n 10,200,000
\n \u00a0
\n 3,053,177,399<\/p>\n
20 July 2026
\n 195,000
\n 329.69
\n 64,289,125<\/p>\n
21 July 2026
\n 190,000
\n 324.17
\n 61,591,795<\/p>\n
22 July 2026
\n 190,000
\n 321.63
\n 61,108,864<\/p>\n
23 July 2026
\n 190,000
\n 313.46
\n 59,557,220<\/p>\n
24 July 2026
\n 195,000
\n 321.25
\n 62,644,500<\/p>\n
Accumulated under the programme
\n 11,160,000
\n \u00a0
\n 3,362,368,903<\/p>\n
\u00a0<\/p>\n
The details for each transaction made under the share repurchase programme are published on novonordisk.com.<\/p>\n
\u00a0<\/p>\n
With the transactions stated above, Novo Nordisk owns a total of 43,104,480 B shares of DKK
\n0.10 as treasury shares, corresponding to 1.0% of the share capital. The total amount of A and B shares in the company is
\n4,465,000,000 including treasury shares.<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Page 2 of 2<\/p>\n
\u00a0<\/p>\n
Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion
\nduring a 12-month period beginning 4 February 2026. As of 24 July 2026, Novo Nordisk has since 4 February 2026 repurchased a total 25,919,179
\nB shares at an average share price of DKK 276.33 per B share equal to a transaction value of DKK 7,162,368,893.<\/p>\n
\u00a0<\/p>\n
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark.
\nOur purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific
\nbreakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 68,800
\npeople in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B).
\nIts ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn
\nand YouTube.<\/p>\n
\u00a0<\/p>\n
Contacts for further information<\/p>\n
\u00a0<\/p>\n
Media:
\n \u00a0<\/p>\n
Ambre James-Brown
\n Liz Skrbkova (US)<\/p>\n
+45 3079 9289
\n +1 609 917 0632<\/p>\n
globalmedia@novonordisk.com
\n USMediaRelations@novonordisk.com<\/p>\n
\u00a0
\n \u00a0<\/p>\n
Investors:
\n \u00a0<\/p>\n
Michael Novod<\/p>\n
Sina Meyer<\/p>\n
+45 3075 6050<\/p>\n
+45 3079 6656<\/p>\n
nvno@novonordisk.com
\n azey@novonordisk.com<\/p>\n
\u00a0
\n \u00a0<\/p>\n
Max Ung
\n Christoffer Sho Togo Tullin<\/p>\n
+45 3077 6414<\/p>\n
+45 3079 1471<\/p>\n
mxun@novonordisk.com
\n cftu@novonordisk.com<\/p>\n
\u00a0
\n \u00a0<\/p>\n
Alex Bruce
\n Mads Berner Bruun<\/p>\n
+45 3444 2613
\n +45 3075 2936<\/p>\n
axeu@novonordisk.com
\n mbbz@novonordisk.com<\/p>\n
\u00a0
\n \u00a0<\/p>\n
Ida Schaap Melvold
\n Frederik Taylor Pitter (US)<\/p>\n
+45 3077 5649
\n +1 609 613 0568<\/p>\n
idmg@novonordisk.com<\/p>\n
fptr@novonordisk.com<\/p>\n
\u00a0<\/p>\n
Novo Nordisk A\/S<\/p>\n
Investor Relations<\/p>\n
Novo All\u00e9 1<\/p>\n
2880 Bagsv\u00e6rd<\/p>\n
Denmark<\/p>\n
Telephone:<\/p>\n
+45 4444 8888<\/p>\n
www.novonordisk.com
CVR no: 24 25 67 90<\/p>\n
\u00a0\u00a0\u00a0Company
\n announcement No 44 \/ 2026<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
SIGNATURES<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
\nduly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.<\/p>\n
\u00a0<\/p>\n
Date: July 27, 2026<\/p>\n
\u00a0<\/p>\n
NOVO NORDISK A\/S<\/p>\n
\u00a0<\/p>\n
Maziar Mike Doustdar<\/p>\n
Chief Executive Officer<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"\u00a0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 \u00a0 ________________ \u00a0 FORM 6-K ________________ \u00a0 REPORT…\n","protected":false},"author":2,"featured_media":135997,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[65834,26,26873,31511,272,3859,358,3348,26872],"class_list":["post-135996","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-buyback-programme","tag-denmark","tag-dkk-15-billion","tag-form-6-k","tag-novo-nordisk","tag-nvo","tag-pharmaceuticals","tag-share-repurchase","tag-treasury-shares"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116992495452957004","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/135996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=135996"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/135996\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/135997"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=135996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=135996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=135996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}